http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102453001-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D217-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D265-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-541 |
| filingDate | 2010-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102453001-B |
| titleOfInvention | Thiomorpholine compounds and its production and use |
| abstract | The present invention relates to thiomorpholine compounds and its production and use. Specifically, the present invention relates to the compound of formula (I) or its pharmaceutically acceptable salt, free alkali, solvate, ester, prodrug, stereoisomer, geometric isomer, racemate, wherein each symbol is as used in the description. The invention still further relates to the pharmaceutical composition comprising the compounds of this invention, the compounds of this invention is used for treating and/or preventing and the purposes in the medicine of DPP-IV hyperactivity or the method for the disease relevant with DPP-IV overexpression or disease in preparation, and the method using the compounds of this invention treatment relevant disease. The compounds of this invention has the effective activity suppressing DPP-IV. |
| priorityDate | 2010-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 289.